Vertex Gears Up For Next Generation In CF Therapy
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals Inc.'s newest cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) has exceeded Wall Street projections for prescriptions and patient starts, the company reported during its third quarter earnings call Oct. 28.
You may also be interested in...
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m
Moderna Therapeutics LLC extended its dealmaking streak and signaled a shift for its collaborative strategy by signing a partnership with Vertex Pharmaceuticals Inc. to develop a cystic fibrosis (CF) therapy based on the private biotechnology firm's messenger RNA (mRNA)-based drug development technology.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.